Galapagos to present data on CAR T-cell therapy candidates GLPG5101 and GLPG5201

Galapagos (GLPG) announced that it will present new data from its CAR T- and TCR T-cell therapy pipeline at the 66th American Society of Hematology ASH Annual Meeting and Exposition in San Diego, CA, 7-10 December. Three abstracts, including one oral presentation, will feature new data from our proprietary cell therapy programs in relapsed/refractory non-Hodgkin lymphoma , and R/R chronic lymphocytic leukemia and Richter transformation in addition to preclinical data in head & neck cancer, developed in partnership with Adaptimmune. Galapagos will also host a company showcase, titled: Fresh, Fit, and Fast: Pioneering the Future of Cell Therapy through Decentralized Manufacturing. “We are committed to advancing breakthrough innovations to expand the reach of cell therapies for patients with rapidly progressing cancers,” said Jeevan Shetty, MD, Head of Clinical Development Oncology at Galapagos. “We are excited to present promising new clinical data for our CD19 CAR T-cell therapy candidates, which continue to support the hypothesis that delivering fresh, fit cells quickly could improve outcomes for patients. Additionally, the preclinical proof-of-concept data we will present with our partner Adaptimmune highlight the potential of our innovative approach in treating solid tumors, expanding our reach to critically-ill patients beyond hematological cancers.”